We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why the Market Dipped But Doximity (DOCS) Gained Today
Read MoreHide Full Article
In the latest trading session, Doximity (DOCS - Free Report) closed at $26.03, marking a +1.32% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.38%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.13%.
The stock of medical social networking site has risen by 17.52% in the past month, leading the Medical sector's gain of 0.6% and the S&P 500's gain of 11.41%.
Market participants will be closely following the financial results of Doximity in its upcoming release. The company plans to announce its earnings on May 13, 2026. On that day, Doximity is projected to report earnings of $0.28 per share, which would represent a year-over-year decline of 26.32%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $143.67 million, up 3.89% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $643.12 million, indicating changes of +8.45% and +12.75%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.56% higher. Doximity is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note Doximity's current valuation metrics, including its Forward P/E ratio of 16.16. Its industry sports an average Forward P/E of 24.84, so one might conclude that Doximity is trading at a discount comparatively.
It's also important to note that DOCS currently trades at a PEG ratio of 1.28. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.44.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 167, positioning it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why the Market Dipped But Doximity (DOCS) Gained Today
In the latest trading session, Doximity (DOCS - Free Report) closed at $26.03, marking a +1.32% move from the previous day. The stock outpaced the S&P 500's daily loss of 0.38%. Elsewhere, the Dow saw a downswing of 0.63%, while the tech-heavy Nasdaq depreciated by 0.13%.
The stock of medical social networking site has risen by 17.52% in the past month, leading the Medical sector's gain of 0.6% and the S&P 500's gain of 11.41%.
Market participants will be closely following the financial results of Doximity in its upcoming release. The company plans to announce its earnings on May 13, 2026. On that day, Doximity is projected to report earnings of $0.28 per share, which would represent a year-over-year decline of 26.32%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $143.67 million, up 3.89% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $1.54 per share and revenue of $643.12 million, indicating changes of +8.45% and +12.75%, respectively, compared to the previous year.
Investors should also pay attention to any latest changes in analyst estimates for Doximity. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.56% higher. Doximity is holding a Zacks Rank of #2 (Buy) right now.
Investors should also note Doximity's current valuation metrics, including its Forward P/E ratio of 16.16. Its industry sports an average Forward P/E of 24.84, so one might conclude that Doximity is trading at a discount comparatively.
It's also important to note that DOCS currently trades at a PEG ratio of 1.28. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Medical Info Systems industry had an average PEG ratio of 1.44.
The Medical Info Systems industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 167, positioning it in the bottom 32% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.